CU Programme of Idarucizumab for Japanese Patients

Summary

The objective is to collect the safety data of idarucizumab for patients treated with dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of uncontrolled or life-threatening bleeding or when emergency surgery or urgent procedures are required.

Timeline

Start

2016-07-22

Primary completion

2016-09-16

Completion

2016-09-16

Drugs

Indications